Inferra AI / Company / URGN
UroGen Pharma Ltd.
URGN · Health Care
Last earnings Aug 5, 2026
Key results
Revenuequarter
$24.2 million
JELMYTO (mitomycin) for pyelocalyceal solution in LG-UTUC: Generated net product revenue of $24.2 million in the quarter ended June 30, 2025, an increase of 11% compared to the same quarter in 2024, driven by underlying demand growth of 7% and year-over-year price favorability.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Second Quarter 2025 Financial Results JELMYTO Revenue: JELMYTO net product revenues were $24.2 million for the three months ended June 30, 2025, compared with $21.8 million for the same quarter of 2024.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Year-over-year revenuequarter
11%
Year-over-year revenue growth of 11% was driven by underlying demand growth of 7% and price favorability.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 7, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $24.2 million | — | — |
| Year-over-year revenue | 11% | — | — |
Guidance · company-stated
Direction: Reiterated
“2025 JELMYTO Revenue and Company Operating Expense Guidance: Guidance for full-year 2025 net product revenues for JELMYTO remains unchanged and is expected to be in the range of $94 to $98 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Interest Expense on Long-Term Debt: Interest expense related to the $125 million term loan facility with funds managed by Pharmakon Advisors was $4.1 million in the second quarter of 2025, compared to $3.5 million in the same period in 2024.
The Company accounts for its investments, which include cash equivalents and marketable securities, as available-for-sale in accordance with the Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) Topic 320, Investments Debt and Equity Securities .
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +305.0% computed from stated figures
Event summary
UroGen Pharma Ltd. Q2 2025 — JELMYTO (mitomycin) for pyelocalyceal solution in LG-UTUC: Generated net product revenue of $24.2 million in the quarter ended June 30, 2025, an increase of 11% compared to the same quarter in 2024, d…
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Reiterated
Revenue: “2025 JELMYTO Revenue and Company Operating Expense Guidance: Guidance for full-year 2025 net product revenues for JELMYTO remains unchanged and is expected to be in the range of $94 to $98 million.”
Revenue — Reiterated (“remains unchanged”)
“2025 JELMYTO Revenue and Company Operating Expense Guidance: Guidance for full-year 2025 net product revenues for JELMYTO remains unchanged and is expected to be in the range of $94 to $98 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Interest Expense on Long-Term Debt: Interest expense related to the $125 million term loan facility with funds managed by Pharmakon Advisors was $4.1 million in the second quarter of 2025, compared to $3.5 million in the same period in 2024.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The Company accounts for its investments, which include cash equivalents and marketable securities, as available-for-sale in accordance with the Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) Topic 320, Investments Debt and Equity Securities .
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) within the condensed consolidated statements of shareholders deficit.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
Long-Term Debt The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
With a solid balance sheet, we are well positioned to fully support the launch of ZUSDURI while advancing strategic business initiatives to drive sustained growth and innovation.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The success of the Company depends on its ability to successfully commercialize its technologies to support its operations and strategic plan.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
11 Table of Contents As a basis for considering such assumptions, a three -tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
In accordance with the Company s general investment strategy, the Company does not intend to sell the investments before maturity.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a first priority security interest in Jelmyto, Zusduri , UGN- 103 and UGN- 104, including the regulatory approvals, intellectual property, material agreements, proceeds and accounts receivable related to these products.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
Words such as can, continue, estimate, expect, may, plan, potential, will, or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025, as well as the Risk Factors section of UroGen s Quarterly Report on Form 10-Q being filed with the SEC later today, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen s actual results could differ materially and adversely from those anticipated or implied thereby.
SEC original ↗UroGen Pharma Ltd. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Legal Proceedings 40 Item 1A.
SEC original ↗UroGen Pharma Ltd. — 10-Q Quarterly report10-QAug 5, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q2 2026
- 8-KURGN
Aug 20, 2026
- 8-KURGN
Aug 5, 2026
- 10-QURGN
Aug 5, 2026
- Q1 2026
- 8-KURGN
Jun 23, 2026
- 8-KURGN
Jun 2, 2026
- 8-KURGN
May 6, 2026
- 10-QURGN
May 6, 2026
- Q4 2025
- 8-KURGN
Mar 2, 2026
- 8-KURGN
Mar 2, 2026
- 10-KURGN
Mar 2, 2026
- Q3 2025
- 8-KURGN
Nov 6, 2025
- 10-QURGN
Nov 6, 2025
- Q2 2025
- 8-KURGN
Aug 27, 2025
- 8-KURGN
Aug 7, 2025
- 10-QURGN
Aug 7, 2025
- 8-KURGN
Jul 3, 2025
- Q1 2025
- 8-KURGN
Jun 13, 2025
- 8-KURGN
May 12, 2025
- 10-QURGN
May 12, 2025
- Q4 2024
- 8-KURGN
Mar 10, 2025
- 10-KURGN
Mar 10, 2025
- 8-KURGN
Feb 20, 2025
- 8-KURGN
Jan 14, 2025
- Q3 2024
- 8-KURGN
Nov 6, 2024
- 10-QURGN
Nov 6, 2024
- 8-KURGN
Oct 9, 2024
- Q2 2024
- 8-KURGN
Sep 24, 2024
- 8-KURGN
Sep 13, 2024
- 8-KURGN
Aug 15, 2024
- 10-QURGN
Aug 13, 2024
Earnings releases
8 documentsPresentations
0 documentsNo presentations for UroGen Pharma Ltd. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for UroGen Pharma Ltd. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.